Highlight
– Ammoxetine, a novel selective serotonin-norepinephrine reuptake inhibitor (SNRI), was evaluated in a multicenter, placebo-controlled phase 2 trial in adults with major depressive disorder (MDD).
– Both 40 mg/d and 60 mg/d doses significantly reduced depressive symptoms compared with placebo over 8 weeks.
– The safety profile was generally favorable, with mostly mild to moderate adverse events.
– Ammoxetine offers potential advantages over existing antidepressants by reducing hepatotoxicity and improving tolerability.